2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Epigenetics
  4. PARP
  5. PARP12 Isoform

PARP12

PARP12 is a zinc-finger-containing mono-ADP-ribosyltransferase that functions as an interferon-stimulated antiviral effector and regulates protein mono-ADP-ribosylation in innate immune responses[1][6]. Mechanistically, PARP12 localizes to cytoplasmic stress granules through its zinc-finger domains, where it contributes to antiviral defense by repressing translation, interacting with viral RNA, and promoting restriction of viral replication[1][7]. PARP12 also directly modifies viral targets, including Zika virus non-structural proteins NS1 and NS3, leading to their ubiquitination-associated proteasomal degradation and suppression of viral propagation[6][7]. In experimental infection models, PARP12 restricts replication of multiple RNA viruses, including alphaviruses, flaviviruses, coronaviruses, and encephalomyocarditis virus, supporting its central role in host antiviral immunity[7][2][3]. Recent studies further demonstrated that PARP12 is required for efficient restriction of viral macrodomain mutants and participates in interferon-dependent antiviral pathways[3][4]. Compared with the related zinc-finger PARP family member PARP13/ZAP, which lacks catalytic ADP-ribosyltransferase activity and primarily mediates RNA recognition and degradation, PARP12 possesses intrinsic mono-ADP-ribosyltransferase activity and directly modifies protein substrates[7][8]. Beyond antiviral signaling, PARP12 has been implicated in intracellular trafficking through MARylation-dependent regulation of transport machinery, indicating broader cellular functions that may influence disease-relevant pathways[5]. Therefore, PARP12 represents a valuable experimental target for investigating ADP-ribosylation-dependent antiviral mechanisms and innate immune regulation[1][7].

PARP12 Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-148754
    PARP10-IN-3
    		Inhibitor 98.72%
    PARP10-IN-3 is a selective mono‐ADP‐ribosyltransferase PARP10 inhibitor with an IC50 of 480 nM for human PARP10. PARP10-IN-3 reveals potent inhibition on PARP2 and PARP15 with IC50s of 1.7 μM for human PARP2 and human PARP15, respectively.
  • HY-148753
    PARP10-IN-2
    		Inhibitor 98.02%
    PARP10-IN-2 is a potent mono‐ADP‐ribosyltransferase PARP10 inhibitor with an IC50 of 3.64 μM for human PARP10. PARP10-IN-2 reveals potent inhibition on PARP2 and PARP15 with IC50s of 27 μM and 11 μM for human PARP2 and human PARP15, respectively.
  • HY-155993
    YCH1899
    		Inhibitor 99.39%
    YCH1899 is an orally active PARP inhibitor, with an IC50< 0.001 nM for PARP1/2. YCH1899 exhibits distinct antiproliferation activity against Olaparib (HY-10162)-resistant and Talazoparib (HY-16106)-resistant Capan-1 cells (Capan-1/OP and Capan-1/TP cells) , with IC50 values of 0.89 and 1.13 nM, respectively. YCH1899 has acceptable pharmacokinetic properties in rats.
  • HY-172806
    PARP14 inhibitor 1
    		Inhibitor
    PARP14 inhibitor 1 is an orally active, selective PARP14 inhibitor with an IC50 of 5.52 nM. PARP14 inhibitor 1 exhibits favorable pharmacokinetic properties and in vivo safety. PARP14 inhibitor 1 enhances and stabilizes intracellular endogenous PARP14 protein levels, while effectively reducing the expression levels of IL-4, IL-13 and IL-17A. PARP14 inhibitor 1 can be used in research related to atopic dermatitis.